ImpriMed is thrilled to announce that, on November 1st 2022, we will be upgrading the CHOP therapy section of our Personalized Prediction Profile with more powerful artificial intelligence (AI) models and an easy-to-read report format that provides faster access to critical information.
Our CHOP prediction report provides you with the likelihood that your individual patient’s cancer will go into complete remission (CR) after different durations of CHOP therapy and the longevity of the remission that your patient is likely to experience. Caregivers can use these predictions to tailor treatment to individual patients by deciding if CHOP therapy is the right option and how long to administer CHOP before exploring alternatives.
Predictions are generated by AI models trained to forecast real-world clinical outcomes collected from naive canine lymphoma patients who underwent CHOP or L-CHOP therapy. Thanks to our ongoing collaboration with the ImpriMed user community, these outcomes now include an expanded dataset of 174 canine lymphoma patients. Our AI predicts these outcomes using multiple sources of patient information, including drug-sensitivity testing, medical history, flow cytometry metrics, and clonality testing.
- The new v2 AI is substantially more accurate at predicting the likelihood of CR than the v1, thanks to the expanded dataset and more powerful AI methods developed by ImpriMed’s data science team.
- Above is an example of the improved v2 report format provides you with separate projections for each of the first two cycles of CHOP therapy, making it easier to decide if you want to continue with CHOP therapy or consider alternatives during the critical first months of treatment.
- Importantly, our v2 report includes a more accurate AI model for the prediction of the longevity of CR with (L-)CHOP therapy.
- The v2 report represents both the patient's individual risk (high or low) category and the median overall time course for other patients in that same risk category in the easy-to-read Kaplan-Meier curve display.
If you have any questions about these updates, please email our support team at support@imprimedicine.com. Thank you.